bioCSL Trivalent Influenza Virus Vaccine

The bioCSL Trivalent Influenza Virus Vaccine is an inactivated, split-virion seasonal influenza vaccine formulated to provide active immunization against three strains of influenza virus. The trivalent formulation contains two influenza A subtypes (H1N1 and H3N2) and one influenza B virus (B/Victoria lineage). The specific viral strains included are selected annually based on global surveillance data and recommendations from health authorities such as the FDA and WHO. For the 2024–2025 season, the recommended composition includes an A(H1N1)pdm09-like virus, an A(H3N2)-like virus, and a B/Victoria-lineage-like virus[1][2][5]. The vaccine works by inducing neutralizing antibodies against hemagglutinin surface proteins of the included viruses, thereby preventing infection or reducing disease severity upon exposure to circulating strains. It is indicated for annual vaccination to prevent seasonal flu in individuals aged 6 months and older[2][5]. Developed originally by bioCSL (now part of CSL Seqirus), this product is manufactured using egg-based technology.

Brand names

bioCSL Trivalent Influenza Virus Vaccine

Other names

CSL Seqirus trivalent influenza vaccineAfluria Trivalent (historical)bioCSL TIV